$24.99
Research Studies:
Out of stock
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
GHRP-6 2mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
GHRP-6 2mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
| CAS No. | 87616-84-0 |
|---|---|
| Purity | ≥99% |
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Molecular Formula | C46H56N12O6 |
| Molecular Weight | 873.01 g/mol |
| Applications | Growth hormone stimulation, muscle development research, metabolic function studies |
| Synthesis | Solid-phase synthesis |
| Format | Lyophilized powder |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Consider these supplementary peptides for a comprehensive research approach.
Researchers who buy GHRP-6 for research are usually evaluating a synthetic hexapeptide in the GH secretagogue and ghrelin receptor literature, not seeking consumer-use guidance [1] [2]. This product-page guide explains how Pure Lab Peptides frames GHRP-6 peptide identity, COA documentation, analytical testing, lot traceability, and RUO labeling for laboratory research. It also separates published pathway literature from product claims so procurement teams can review documentation without turning academic context into personal-use positioning.
To buy GHRP-6 for research, researchers should review RUO labeling, compound identity, batch-specific COA details, HPLC purity information, LC-MS or mass spectrometry identity support, lot traceability, and storage records before procurement. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Analytical-method documentation supports identity, quality, purity, and method suitability review [5].
The first documentation signal is consistency. The compound name, synonym set, lot number, catalog listing, COA, and label should all point to the same research material.
For GHRP-6 peptide review, the most useful early records are the product listing, certificate of analysis, identity-testing support, purity-testing method, report date, and storage notes. FDA analytical-method guidance describes identity, quality, purity, and potency as documentation targets in regulated analytical submissions, which is a useful benchmark for research-material document review [5].
The phrase buy GHRP-6 is commercial by itself, so this page reframes it as buy GHRP-6 for research. That shift matters because the article is about research procurement, not consumer selection, product performance, or personal-use outcomes.
For Pure Lab Peptides, commercial research intent means the page should help laboratory buyers evaluate documentation. It should not turn search language into claims about what a compound does outside documented experimental settings.
RUO labeling should appear before deeper procurement review because it defines the context for the page. In an IVD-specific FDA guidance context, RUO labeling is treated as distinct from diagnostic positioning; the same editorial principle is useful here because research-product copy must remain separate from diagnostic, clinical-use, or therapeutic framing [6].
For a research peptide listing, RUO labeling should be visible, direct, and consistent across the product page and documentation. It should not be weakened by consumer-facing claims.
GHRP-6 product-page content should help qualified research and laboratory teams evaluate identity, testing, traceability, and published literature context. It should not function as a wellness article, clinical guide, or personal-use buying guide.
The safest framing is simple: Pure Lab Peptides supplies GHRP-6 as a research material, and the page exists to help research buyers evaluate documentation before procurement.
RUO positioning requires clear boundaries. The page can explain that GHRP-6 is discussed in GH secretagogue, ghrelin receptor, and endocrine pathway literature, but it cannot convert that literature into a claim for a product listing [3].
It should also make the procurement task practical. Researchers should be able to locate the COA, compare lot details, review analytical testing, and confirm that documentation supports the product identity.
Product copy should use neutral verbs such as “describes,” “examines,” “characterizes,” and “reports.” Those verbs keep the focus on published literature and documentation.
A GHRP-6 research page should not imply outcomes for people, animals, wellness, appearance, fitness, or body-composition goals. If literature mentions sensitive areas, the article should keep those references in an evidence-boundary context.
GHRP-6 is a synthetic peptide compound commonly discussed under growth hormone-releasing peptide-6, GH-releasing hexapeptide 6, and GHRP6 synonym variants [2]. In research literature, it is generally classified with growth hormone-releasing peptides and growth hormone secretagogue research [3].
Its literature context is biochemical and endocrine-focused. The compound appears in studies of pituitary-cell signaling, ghrelin receptor activity, and GH release models, not in product-use guidance.
PubChem lists GHRP-6 with the formula C46H56N12O6 and a computed molecular weight of about 873.0 g/mol [1]. IUPHAR/BPS classifies GHRP-6 as a peptide ligand and links it to synonym records used in receptor and pharmacology databases [2].
The peptide sequence is often represented in literature as His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, a sequence notation reported in early GHRP-6 pituitary-cell research [7]. Sequence, molecular weight, and synonym consistency are useful identity checks in documentation review.
Hexapeptide classification means the molecule contains six amino acid residues. That classification helps distinguish GHRP-6 from longer polypeptides, peptide fragments, and non-peptide secretagogue compounds.
This matters for documentation because peptide synthesis, identity testing, and impurity review can be shaped by chain length, residue composition, and structural features. Modern synthetic peptides are commonly assembled using solid-phase peptide synthesis methods, with Fmoc-based approaches widely discussed in peptide synthesis literature [8].
GHRP6, GHRP-6, GH-releasing hexapeptide 6, and growth hormone-releasing peptide-6 can all appear in research records. IUPHAR/BPS lists several of these synonyms on the GHRP-6 ligand page [2].
Synonym review prevents mismatches between product listings, COAs, chromatogram labels, and lab records. It also helps research teams avoid confusing GHRP-6 with other GHRPs or same-lane GH secretagogue research compounds.
Research buyers should evaluate GHRP-6 as a documented laboratory material. The commercial question is not simply whether it is available for research; it is whether the product page and supporting records give enough information for a responsible procurement review.
A strong product-page record should connect the catalog name, lot number, COA, purity method, identity method, and storage notes into one coherent documentation set.
A research material listing should show the compound name, research-use-only positioning, lot-specific documentation availability, and analytical testing overview. If a listing includes a quantity such as GHRP-6 5mg, that detail should remain a catalog specification.
The listing should not create a separate product-variant article or imply a research application based on catalog quantity. The canonical entity remains GHRP-6.
Buy GHRP-6 for research belongs in the procurement stage after research teams have evaluated documentation. The phrase should lead to COA review, lot traceability, and analytical verification, not to consumer outcome framing.
For product-page SEO, this lets Pure Lab Peptides serve commercial research intent without drifting into unsupported product claims.
Growth hormone secretagogue research developed around compounds that interact with the GH secretagogue receptor, also known as the ghrelin receptor [4] [9]. GHRP-6 appears in that literature as one of several synthetic growth hormone-releasing peptides [3].
The scientific background includes endocrine pathway models involving the pituitary gland, hypothalamic signaling, GHRH context, ghrelin receptor signaling, and downstream endocrine markers. Those topics are literature context only.
IUPHAR/BPS notes that GHRP-6 and related hexapeptides are known as ghrelin receptor agonists in pharmacology literature [9]. Early research also describes GHRP-6 in relation to growth hormone release from pituitary-cell models [7].
This classification supports receptor-pathway discussion. It does not create a product claim for a research-use-only material.
GHRH belongs in the same endocrine research lane because published pituitary-cell literature has compared GHRP-6 and GHRH signaling in GH release models [7]. The GH/IGF-1 axis is a broader endocrine framework, and insulin-like growth factor-1 appears in endocrine literature as a downstream marker rather than a product-page claim [10].
A careful page can mention GHRH and IGF-1 as literature context while keeping the product listing focused on identity, COA, and analytical documentation.
Mechanism of action should be handled as a literature concept, not a product promise. In GHRP-6 research, the mechanism context includes ghrelin receptor interaction, GHSR signaling, pituitary-cell models, and intracellular signaling pathways [4] [9].
The key boundary is that model-specific pathway observations do not become instructions, claims, or product outcomes.
NCBI Gene identifies GHSR as the growth hormone secretagogue receptor and describes the functional isoform as the receptor for ghrelin, defining a neuroendocrine pathway for growth hormone release [4]. IUPHAR/BPS notes that GHRP-6 is among the synthetic peptide secretagogues associated with ghrelin receptor activity [9].
Ghrelin itself was identified as an endogenous ligand for the growth hormone secretagogue receptor in landmark literature [11]. GHRP-6 research is best read inside that receptor and pathway context.
GHSR is a G protein-coupled receptor, and the literature describes signaling through pathways that include phospholipase C, inositol trisphosphate, calcium signaling, and protein kinase C-related mechanisms [12]. GHRP-6 studies in pituitary-cell models have also reported calcium-related signaling and PKC involvement [13] [14].
These details help researchers interpret published mechanism of action discussions. They should not be converted into product-performance statements.
Growth hormone release belongs in the scientific background, not in a product claim. Early studies examined the action of GHRP-6 in pituitary-cell models and described GH secretion or GH release under defined experimental settings [7] [13].
A product page can acknowledge that literature. It should then return to documentation: identity, purity, analytical testing, and RUO status.
Published GHRP-6 research includes receptor pharmacology, GH secretagogue literature, pituitary-cell studies, and broader endocrine pathway reviews. Review literature also places GHRPs within a class of synthetic peptides developed for secretagogue research [3] [15].
The safest editorial approach is to describe what studies examine. Do not imply that a Pure Lab Peptides product is equivalent to, approved for, or intended for the same context as any specific study material.
Preclinical literature can support pathway interpretation, model selection, and evidence boundaries. It cannot support product-use claims for a research material.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | GHRP-6 formula, molecular weight, synonyms, and peptide classification [1] [2] | Database and pharmacology records | Supports identity review, not application claims |
| Receptor pathway | GHSR, ghrelin receptor activity, and related signaling models [4] [9] [12] | Database, receptor, and review literature | Supports mechanism context only |
| Pituitary-cell signaling | GHRP-6 exposure in controlled pituitary-cell research settings [7] [13] [14] | Preclinical and in vitro literature | Supports model-specific interpretation |
| Analytical review | HPLC, LC-MS, and mass spectrometry methods for peptide characterization [5] [16] | Analytical guidance and peer-reviewed review | Supports documentation review |
This evidence ladder keeps the article grounded: database identity first, receptor context second, model-specific literature third, and documentation review throughout.
In vitro models can isolate receptor or cell-signaling questions under controlled laboratory conditions. GHRP-6 has been examined in pituitary-cell systems where researchers observed GH secretion, calcium signaling, and PKC-related pathways [13] [14].
Those findings are valuable for research interpretation. They should remain tied to model conditions and should not be translated into claims about research materials.
Evidence interpretation means reading the literature without overstating it. A research page can explain that published studies examined receptor signaling, biochemical cascades, or GH release models while also stating that product pages should not claim outcomes.
Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.
Study findings belong to the model, method, and study design. Product positioning belongs to the research material listing and documentation.
This separation matters when terms from literature could sound like consumer-facing or clinical-use language. RUO product pages should keep those terms separate from the product listing and focus on COA review, analytical testing, identity verification, and lot traceability.
Pathway relevance means a molecule is discussed in a pathway or receptor context. It does not mean the material is positioned for a product application.
For GHRP-6, ghrelin receptor and GHSR literature may explain why researchers evaluate the peptide in endocrine pathway models [4] [9]. The product page should still focus on documentation and research procurement.
A certificate of analysis should help research teams connect the listed material to batch-specific analytical records. The COA is not a substitute for scientific interpretation, but it is central to research procurement.
For GHRP-6 peptide review, the COA should be checked against the product page, label, lot number, and testing details. FDA method-validation guidance emphasizes documentation that supports identity, quality, purity, and related analytical attributes [5].
A useful COA should identify the compound name, lot or batch number, report date, test method, purity result, identity-testing reference, and lab or reviewer information when available. These details help determine whether the record belongs to the exact research material being evaluated.
For peptides, COA review is stronger when purity and identity are not treated as the same thing. HPLC may support purity review, while LC-MS or mass spectrometry can support identity and impurity characterization [16].
Batch-specific documentation links a research material to a particular production and testing record. Without that link, procurement teams may not be able to connect a COA to the material under review.
Traceability is also useful for internal lab records. A lot number, COA date, product label, and storage documentation should tell the same story.
COA dates help research buyers understand when analytical testing was reported. A current-looking product page does not automatically mean the COA is current for the lot being reviewed.
Research teams should compare the COA date against the product label, lot number, and inventory documentation. This is a documentation check, not a product-performance claim.
Peptide purity and peptide identity are related but different review targets. Purity describes the proportion of the main detected component under a stated analytical method, while identity asks whether the material corresponds to the intended compound.
Analytical guidance and peptide characterization literature both support the use of method-specific evidence rather than generic quality language [5] [16].
High-performance liquid chromatography separates components in a sample and is commonly used to evaluate purity through chromatographic data. USP chromatography standards describe chromatographic terms and system suitability concepts used in separation methods [17].
For a GHRP-6 COA, HPLC information is most useful when the method, chromatogram, retention-time information, and purity result are clearly tied to the lot record.
Identity testing helps confirm that the detected compound is consistent with GHRP-6. For peptides, mass spectrometry is well suited to identity and purity-related analysis when applied with appropriate method controls [18].
Identity review should compare the expected molecular weight, sequence notation, synonym set, and analytical output. A purity percentage alone does not confirm complete compound identity.
HPLC and LC-MS answer different documentation questions. HPLC supports chromatographic purity review, while LC-MS adds mass-based characterization that can support identity and impurity review [16] [18].
A strong analytical verification workflow does not rely on one field alone. It compares product-page identity, COA data, HPLC output, LC-MS or mass spectrometry support, and batch-specific records.
LC-MS combines chromatographic separation with mass-based detection. In synthetic peptide characterization literature, LC-MS is used to evaluate impurities and support structural characterization workflows [16].
For GHRP-6 research procurement, LC-MS support is useful when the mass data align with the expected molecule and the lot-level record. It should be reviewed as documentation, not as a claim about research application.
Mass spectrometry adds mass-to-charge information that can help confirm whether analytical signals align with the expected peptide. Peptide analysis literature describes mass spectrometry as suitable for synthetic peptide identity and purity evaluation when method context is adequate [18].
Documentation-only lab-test verification workflow:
Lot traceability is the link between a physical research material and its documentation set. For GHRP-6, that means the lot number should match across the product label, COA, analytical records, and procurement file.
This review protects the integrity of research documentation. It does not evaluate product outcomes.
Lot numbers matter because peptide identity and purity records are batch-specific. If the lot number does not match, the COA may not support the material being reviewed.
This is especially important for synthetic peptides because impurity profiles and analytical outputs can vary across production lots. LC-MS literature on synthetic peptide characterization emphasizes detailed impurity characterization as part of a risk-based control strategy [16].
A chain-of-documentation connects listing, label, COA, analytical report, storage note, and internal procurement record. Each item should be clear enough to review later.
For laboratory research, this supports reproducibility and audit readiness. It also helps separate documentation facts from claims that the product page should not make.
Labeling, storage, and handling documentation should be simple and consistent. The product label should identify the material, show RUO status, and match the lot-level record.
Storage documentation should preserve stated conditions in a lab record without turning the page into practical material-preparation guidance. WHO storage and distribution guidance highlights the importance of documented storage and distribution activities across supply chains [19].
RUO labels should make the research context clear. They should not suggest consumer, clinical, diagnostic, veterinary, wellness, cosmetic, or fitness positioning.
For GHRP-6, the label should support the same research-only framing used in the product page and COA. Consistency matters more than promotional language.
Lyophilized peptide records support review by documenting the material state and stated storage conditions. Peptide storage and handling literature for mass spectrometry-based assays emphasizes the importance of controlled storage, documentation, and peptide-specific handling considerations [20].
The product page should not turn lyophilized status into application guidance. It should keep the focus on recordkeeping, storage notes, and batch traceability.
Common misunderstandings usually come from collapsing literature, product listings, and search intent into one claim. A safer approach keeps each layer separate.
GHRP-6 research pages should answer procurement and documentation questions first. Literature interpretation should remain model-specific.
Published literature does not equal product-use guidance. A study may examine receptor signaling, gh secretion, pituitary-cell behavior, or endocrine markers, but the product page should not present those observations as product claims [7] [13].
Common misunderstandings to avoid:
Search intent can drift when commercial phrases are expanded with consumer outcomes, clinical-use language, or product-performance claims. That drift weakens RUO positioning.
For GHRP-6, the safer copywriting path is clear: keep the article centered on research procurement, compound identity, COA review, HPLC, LC-MS, lot traceability, published literature boundaries, and RUO labeling.
Before teams buy GHRP-6 for research, the review should be documentation-led. The strongest procurement process checks identity, COA, purity method, identity support, lot number, storage notes, and RUO labeling in one pass.
This supports commercial research intent without changing the article into a personal-use guide.
Research buyers should compare documentation quality, not claims. Useful supplier-evaluation factors include COA availability, batch-specific records, analytical method visibility, consistent labeling, storage documentation, and clear RUO positioning.
A practical documentation checklist:
The strongest signals are consistent identity records, batch-specific COA details, HPLC purity data, LC-MS or mass spectrometry identity support, lot traceability, clear RUO labeling, and storage documentation. FDA and ICH-aligned analytical guidance both emphasize that method development and validation should be tied to the intended analytical purpose and documented quality attributes [5] [21].
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
Review the product-page documentation, COA details, analytical testing notes, lot traceability, and RUO labeling
GHRP-6 is a research peptide discussed in GH secretagogue receptor and endocrine pathway literature. Scientific databases identify GHRP-6 as a peptide compound, while pharmacology sources list it with growth hormone-releasing peptide-6 synonym records [1] [2]. On an RUO product page, that identity context should support compound characterization, research documentation, and product-document review.
Researchers should consider documentation before they buy GHRP-6 for research. Key review points include RUO labeling, COA availability, lot traceability, supplier documentation, peptide identity records, and analytical testing support. The procurement question is documentation-focused: whether the product listing, label, batch record, and supporting records align for laboratory research.
Researchers review COA documentation for GHRP-6 because it connects a research material to batch-specific information. A COA can help confirm whether the compound name, lot number, purity method, identity testing reference, and report date match the product documentation. It should support research review, not product claims.
Published literature discusses growth hormone secretion in model-specific research settings, including pituitary-cell and receptor-pathway contexts [7] [13]. This type of literature can help researchers understand pathway research, hormone secretion models, and experimental interpretation. It should not be converted into product-positioning claims for RUO materials.
Anterior pituitary gland context helps explain why GHRP-6 appears in endocrine pathway research. Literature has examined pituitary-related signaling models, GH secretagogue receptor activity, and GHRH-related comparisons [4] [7]. For an RUO page, this context belongs in published literature interpretation rather than product application language.
Supplier documentation for research peptides should show consistent product information across the listing, label, COA, lot record, and storage documentation. For GHRP-6, useful documentation supports peptide identity, compound characterization, analytical testing review, and batch-level traceability. The stronger the documentation chain, the easier it is for laboratory buyers to evaluate research materials.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: KAKEN Researcher Profile
Masayasu Kojima’s published work is closely connected to the ghrelin and growth hormone secretagogue receptor literature that provides context for GHRP-6 research. His publications help frame the receptor pathway background, peptide-ligand discovery history, and endocrinology context discussed in this article. The selected work below is relevant to understanding how ghrelin receptor research developed and how pathway-focused literature can be interpreted without turning scientific findings into product claims.
Selected publications:
Author profile: UW Medicine Profile
Andrew N. Hoofnagle’s published work is relevant to the analytical framework used throughout this product-page research guide. His publications support the discussion of peptide-focused mass spectrometry, assay development, storage records, quantification, and documentation practices that can inform laboratory material review. This work is especially useful for interpreting analytical testing language, product documentation, and peptide identity review in a research-use-only context.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around GHRP-6. In GH secretagogue and GHRH research content, terms such as potential benefits, efficacy, sale online, legal to buy, growth hormone levels, hormone stimulation, growth hormone production, and hunger hormone can drift into consumer-facing, clinical-use, wellness, or product-claim language when framed incorrectly. Phrases such as absorption, bioavailability, therapeutic language, and product effects also require careful separation from product positioning.
Here, those phrases are handled only as research-language examples, not product uses, outcomes, instructions, recommendations, or claims. The focus remains on GHRP-6 identity, COA review, analytical testing, peptide purity, lot traceability, research-use-only labeling, product documentation, and published literature boundaries. Any discussion of endocrine pathway literature should stay tied to model-specific research interpretation rather than personal-use guidance or product-performance framing.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.